Kedokteran & Kesehatan editorial
Open AccessOA2023
Epidemiology, Pathophysiology, Diagnosis, and Therapy of Heart Failure With Preserved Ejection Fraction in Japan
This review summarizes current knowledge on heart failure with preserved ejection fraction (HFpEF) in Japan, highlighting epidemiological trends, pathophysiological mechanisms, diagnostic challenges, and potential therapies specific to the Japanese population.
M. Obokata; H. Sorimachi; T. Harada; K. Kagami; Y. Saito; H. Ishiiยท Journal of Cardiac Failureยท 2023ยท DOI 10.1016/j.cardfail.2022.09.018
The core problem
Heart failure (HF) with preserved ejection fraction (HFpEF) is a global health care problem characterized by diagnostic difficulty, limited treatment options, and high morbidity and mortality rates. The prevalence of HFpEF is increasing due to the aging population and the growing burden of cardiac and metabolic comorbidities such as systemic hypertension, diabetes, chronic kidney disease, and obesity. However, the knowledge base is derived primarily from the United States and Europe, and data from Asian countries, including Japan, remain limited. Given that phenotypic differences may exist between Japanese and Western patients with HFpEF, careful characterization may hold promise to deliver new therapy specific to the Japanese population. In this review, the authors summarize the current knowledge regarding the epidemiology, pathophysiology, diagnosis, and potential therapies for HFpEF in Japan.
Innovation
As a narrative review, the authors synthesized existing literature on HFpEF, with a focus on data from Japan and other Asian countries. They compared and contrasted findings with those from Western populations, highlighting differences in epidemiology, pathophysiology, diagnosis, and treatment responses. The review likely involved a comprehensive search of peer-reviewed articles, but specific search strategies and inclusion criteria are not detailed in the provided abstract.
Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF) is a global health care problem characterized by diagnostic difficulty, limited treatment options, and high morbidity and mortality rates. The prevalence of HFpEF is increasing due to the aging population and the growing burden of cardiac and metabolic comorbidities such as systemic hypertension, diabetes, chronic kidney disease, and obesity. However, the knowledge base is derived primarily from the United States and Europe, and data from Asian countries, including Japan, remain limited. Given that phenotypic differences may exist between Japanese and Western patients with HFpEF, careful characterization may hold promise to deliver new therapy specific to the Japanese population. In this review, the authors summarize the current knowledge regarding the epidemiology, pathophysiology, diagnosis, and potential therapies for HFpEF in Japan.
Why it matters
The authors discuss the implications of these findings for clinical practice and research. They emphasize the need for better characterization of HFpEF in the Japanese population to develop targeted therapies. The review highlights gaps in knowledge, particularly regarding the pathophysiology and optimal management of HFpEF in Japan. The authors suggest that future research should focus on identifying phenotypic differences and conducting clinical trials specific to the Japanese population. The discussion also underscores the importance of addressing comorbidities and implementing preventive strategies to reduce the burden of HFpEF.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ